Volume 20, Number 5—May 2014
Research
Treatment Practices, Outcomes, and Costs of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, United States, 2005–2007
Table 1
Characteristic | Study participants, no. (%), n = 135 | All US MDR TB patients, no. (%), n = 370 |
---|---|---|
Sex | ||
M | 68 (50) | 205 (55) |
F |
67 (50) |
164 (44) |
Age, y | ||
Median | 38.2 | |
0–14 | 1 (1) | 13 (4) |
15–24 | 24 (18) | 64 (17) |
25–44 | 62 (46) | 171 (46) |
45–64 | 40 (30) | 91 (25) |
>65 |
8 (6) |
31 (8) |
Race/ethnicity | ||
Hispanic | 42 (31) | 100 (27) |
White† | 4 (3) | 31 (8) |
Black | 14 (10) | 63 (17) |
Asian | 72 (53) | 173 (47) |
Other/unknown |
3 (2) |
3 (1) |
Geographic origin | ||
Foreign born‡ | 118 (87) | 305 (82) |
US born | 17 (13) | 64 (17) |
*Study patients were from California, New York City, and Texas. MDR, multiple-drug resistant; XDR, extensively drug resistant; TB, tuberculosis.
†Statistically significant differences between percentages of study patients and all US MDR TB patients at p<0.05.
‡For 110 participants, median no. years after first entry into United States = 3.5.
Page created: April 16, 2014
Page updated: April 16, 2014
Page reviewed: April 16, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.